ascopubs.org

Concordance among three programmed death-ligand 1 (PD-L1) scoring methods and their association with clinical outcomes of tislelizumab (TIS) monotherapy in esophageal squamous ...

This is an ASCO Meeting Abstract from the 2024 ASCO Gastrointestinal Cancers Symposium. This abstract does not include a full text component.
ascopubs.org

PD-L1 Immunohistochemistry in Gastric Cancer: Comparison of Combined Positive Score and Tumor Area Positivity Across 28-8, 22C3, and SP263 Assays

The clinical application of PD-L1 immunohistochemistry (IHC) testing is complicated by the availability of multiple IHC assays, scoring algorithms, and cutoffs. This study assessed the analytical ...
The American Journal of Managed Care

Serial CT Response Score Predicts OS in Patients With Advanced NSCLC Receiving ICIs

Serial CTRS was developed from routine-care CTs and externally validated across 10 institutions and the phase 1 GARNET trial, covering ICI monotherapy and combinations across all lines. Multivariable ...
Precision Medicine Online

Merck Immunotherapy, Agilent CDx Net FDA Approval for PD-L1-Positive Ovarian Cancer

The agency approved the Keytruda-based regimen after reviewing data from the KEYNOTE-B96 trial, in which Agilent's PD-L1 IHC 22C3 PharmDx test was used to stratify patients.
Medical Xpress

FDA approves pembrolizumab for resectable head and neck cancer with PD-L1 expression

Pembrolizumab, an immune checkpoint inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with resectable locally advanced head and neck squamous ...

KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Plus Paclitaxel ± Bevacizumab, Approved for Certain Adults with PD-L1+ (CPS ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) approved KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ ...